The following list of cancer immunotherapies are available for licensing under U.S. Patent Publication No.: 20220096542.

Augmentation of Natural Killer Cell Activity and Induction of Cytotoxic Immunity Using Leukocyte Lysate Activated Allogeneic Dendritic Cells: StemVacs

Abstract
Stimulation of immunity would be beneficial in various chronic conditions such as viral infections and neoplasia. Autologous dendritic cell therapy has been widely described in the immunotherapy literature and has been approved by the FDA for treatment of prostate cancer. Unfortunately, the need to generate individual doses is costly and limited by ability of the patients to have sufficient starting cell numbers available to generate sufficient dendritic cells. Here we describe the process of preparing allogeneic dendritic cells utilizing a leukocyte lysate based approach. These data support development of StemVacs for conditions that would benefit from NK activation such as cancer and COVID-19..







Melanoma is a dangerous type of skin cancer that develops from melanocytes, the cells that produce melanin, the pigment that gives skin and hair their color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Juvenile melanoma, also known as melanoma in children, is a rare but common skin cancer in children.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lentigo maligna melanoma is a type of skin cancer that develops from a lentigo maligna, a precancerous condition.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Malignant melanoma, also known as melanoma, is a dangerous type of skin cancer that can develop from melanocytes, the cells that produce melanin and give skin its color.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Acral-lentiginous melanoma is a specific type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Amelanotic melanoma, these skin lesions lack melanin, the dark pigment that gives most moles and melanomas their color. Instead, amelanotic melanomas can be clear, white or skin-colored, sometimes with a slight pink, purple or red tint.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Benign juvenile melanoma is an old term for a rare, noncancerous mole called a Spitz nevus.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Nodular melanoma subungal melanoma is a rare and aggressive form of skin cancer that can appear as a nodule under the nail.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Superficial spreading melanoma is a type of skin cancer that is the most common form of melanoma, accounting for 70–80% of cases.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%